Ionis Pharmaceuticals Inc (IONS)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- QualityRevenue shrinking (-8% y/y)-11
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst: Product (clinical trial milestones). Continuation probability: moderate-to-high, as positive enrollment updates and upcoming data readouts sustain pipeline momentum. Informational only — not financial advice.
- Discover the top movers in Thursday's pre-market session.ChartMill · 2026-07-09
- Novartis' Pipeline Building Continues, Pelacarsen Readout Coming SoonSeekingAlpha · 2026-07-07
- Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027Benzinga · 2026-07-06
- Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction - SlideshowSeekingAlpha · 2026-06-25
- Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction TranscriptSeekingAlpha · 2026-06-25
Any AI summary is an interpretation of public news, not advice or a price target.